Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or natasha@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
natasha@zenopa.com
+44 1494 818 053

Testimonials
I was really impressed with the recruitment experience which Zenopa provided. Initially meeting with them face to face was important as we could gage which roles would be right for me.
Daniel , 2013

Bristol-Myers Squibb receives NICE backing for first-line Yervoy treatment

24 July 2014 11:01 in Pharmaceutical Company Product News


Bristol-Myers Squibb receives NICE backing for first-line Yervoy treatmentBristol-Myers Squibb's cancer drug Yervoy has been recommended for a new melanoma indication by the National Institute for Health and Care Excellence (NICE).

The UK regulator has published new guidance endorsing the use of the ipilimumab therapy as a first-line treatment for patients with advanced malignant melanoma when the full tumour cannot be removed, or the cancer has spread to other parts of the body.

Bristol-Myers Squibb has been able to prove the clinical benefits Yervoy can offer in these circumstances and has also agreed a patient access scheme with the Department of Health to sell the drug to the NHS at a discounted price.

Currently, there are few available therapy options for advanced melanoma, a disease for which prognoses are generally poor.

Professor Carole Longson, centre for health technology evaluation director at NICE, said: "New drugs such as ipilimumab can make a real difference. We already recommend it as a second-line treatment and are pleased to be able to extend that recommendation to first-line treatment too."

This comes after the firm announced that it has stopped a phase III trial of a new melanoma drug, nivolumab, earlier than expected due to the positive data generated thus far.ADNFCR-8000103-ID-801737356-ADNFCR

Other news stories from 24/07/2014

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2015 Zenopa Ltd